

199th WPI-IIIS Seminar

Report from the clinical trial evaluating an orexin 2 receptor agonist in patients with Narcolepsy Type 1

Takeda pharmaceuticals announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1.

The trial evaluated TAK-861 in 112 patients, and it demonstrated statistically significant and clinically meaningful improvement in the primary endpoint Maintenance of Wakefulness Test (MWT) compared to placebo at week 8. Improvements in key secondary endpoints including Epworth Sleepiness Scale (ESS) and Weekly Cataplexy Rate (WCR) were statistically significant and clinically meaningful, consistent with the primary endpoint. The majority of patients who completed the trial entered a long-term extension study.



Dr. Masahiro Matsuo

Therapeutic Area Strategy Unit

Takeda Development Center Japan

Takeda Pharmaceutical Company Limited

Date: **Thursday, June 27, 2024**

Time: **10:00 – 11:00**

Venue: **1F Auditorium, IIIS Building**

*** On-site participation only**



IIIS

INTERNATIONAL INSTITUTE FOR INTEGRATIVE
SLEEP MEDICINE



Contact: International Institute for Integrative Sleep Medicine, University of Tsukuba
029-853-5857 (ext.5857) | wpi-iiis-alliance@ml.cc.tsukuba.ac.jp